New daily pill aims to tackle Hard-to-Treat lymphoma
Disease control
Not yet recruiting
This study tests an experimental daily pill called HP-002 in people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. It includes several ly…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Helioson Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC